Kidney involvement is common in patients with acute SARS-CoV-2 infection, and subclinical inflammation and injury may persist for many months, resulting in a progressive decline in kidney function that leads to chronic kidney disease. Continued research is imperative to understand these long-term sequelae and identify interventions to mitigate them.
More than 180 million people have been diagnosed with COVID-19, and approximately 4 million have died worldwide. The short-term survival of these patients will improve as evidence-based therapies continue to be adopted and new treatments become available. Thus, the number of individuals who are at risk of poor long-term outcomes, known as long COVID, will continue to increase.
Approximately 28% of patients who are hospitalized with COVID-19 are diagnosed with acute kidney injury (AKI) and 9% receive kidney replacement therapy1. Infection with SARS-CoV-2 has both direct and indirect effects that can lead to AKI2. Potential direct effects on the kidney include endothelial damage from viral entry, complement activation, local inflammation and collapsing glomerulopathy. However, indirect mechanisms that injure the kidney, such as sepsis, use of nephrotoxic medications, systemic inflammation, hypercoagulability and thromboembolic disease, might be more common than these direct effects. Although it is well known that AKI can lead to chronic kidney disease (CKD), little is known about the long-term effects of COVID-19 on the kidney.
Importantly, the COVID-19 pandemic is likely to have a long-term impact even on patients who have not been infected by the virus, owing to delays in care for chronic diseases, such as CKD, diabetes and hypertension3. This area is understudied but might have the largest impact at the population level and disproportionately affect vulnerable individuals, particularly those with low socioeconomic status and poor access to health care. Studies are urgently needed to investigate this area and confirm the importance of measures to catch up on preventive care for at-risk individuals.
What are the long-term effects of COVID-19 on the kidney? Three issues warrant consideration before we examine the current evidence. First, COVID-19 might affect the kidney in multiple ways and the contribution of these factors might vary over time. Many of the direct and indirect effects of the SARS-CoV-2 virus might persist during recovery after hospital discharge and could lead to repeat episodes of sepsis, recurrent AKI and increased risk of CKD (Fig. 1). Furthermore, a new diagnosis of diabetes mellitus and worsening of cardiovascular disease due to COVID-19 might delay recovery of AKI. Second, the relationship between COVID-19 and CKD is likely to be bidirectional. Mild CKD might increase the risk of COVID-19 and associated AKI, whereas increased severity of AKI might be associated with persistent kidney dysfunction, delayed recovery and/or need for long-term dialysis. Thus, understanding the effects of COVID-19 on the kidney will require use of study designs that account for this complex relationship and access to datasets in which kidney function is well characterized before and after diagnosis of COVID-19. Finally, whether the effects of COVID-19 are unique or similar to those seen in patients with other infections and sepsis is unclear. Initial reports suggest that many sequelae of COVID-19 are similar to those reported in survivors of sepsis and acute respiratory distress syndrome4.
the relationship between COVID-19 and CKD is likely to be bidirectional
A US study that used electronic health records from the Veterans Health Administration (VHA) to conduct a comprehensive assessment of long COVID reported that COVID-19 increased the risk of CKD and that this risk was highest among those who had severe illness5. Among patients who required hospitalization, adverse kidney manifestations, including urinary tract infections, AKI and CKD, occurred even after the first 30 days following diagnosis of COVID-19. Although the researchers used propensity matching, the possibility that these results are due to residual confounding cannot be excluded as some patients might have had subclinical CKD prior to hospitalization for COVID-19. Moreover, the risk of CKD among patients hospitalized with COVID-19 was similar to that of patients hospitalized with influenza.
The findings of the VHA study were similar to those of a study of patients with COVID-19 in China, which found that 35% of patients had reduced kidney function (estimated glomerular filtration rate (eGFR) <90 ml/min/1.73 m2) 6 months after COVID-19 hospitalization. Interestingly, 13% of patients who did not have AKI during hospitalization showed a reduction in eGFR during follow-up6. Additional studies are underway in different populations with multiple control groups to better understand trajectories of kidney function during recovery in patients with COVID-19. These studies may provide additional insights.
Although in many patients serum creatinine returns to normal levels following AKI, the kidneys might not completely recover. Preclinical studies have demonstrated the development and persistence of inflammation, kidney fibrosis, abnormal kidney gene expression profiles and function deficits after ischaemic kidney injury, despite a return of serum creatinine concentrations to normal values. In COVID-19, these underlying pathophysiological mechanisms could be exaggerated together with worsening diabetes or hypertension control. Kidney disease progression in COVID-19 is likely multifactorial and might be driven by ongoing inflammation, intrinsic tubular injury or maladaptive repair, among other pathways. Novel kidney-specific plasma and urine biomarkers might help to discern the dominant underlying aetiologies and predict which patients are at highest risk of CKD after COVID-19 hospitalization7.
To gain a better understanding of the effects of COVID-19 on the kidney, large integrated health-care systems and collaborations that enable rapid collection and analysis of clinical, laboratory and diagnostic data should continue to provide access to their databases for researchers who are investigating the long-term sequelae of COVID-19. For example, the National COVID Cohort Collaborative (N3C) has created a multisite collaborative learning health network with a scalable infrastructure, incorporating multi-organizational clinical data for COVID-19 analytics8. Translational studies in which patients with COVID-19 undergo data and biospecimen collection during hospitalization and recovery are key to understanding clinical and biological outcomes and investigate mechanisms. The NIH is planning to launch a multicentre, observational study of the post-acute sequelae of SARS-CoV-2 infection (PASC), with a special emphasis on cardiovascular and brain disorders9. The inclusion of novel and traditional measures of kidney function and injury in the PASC study will be important to investigate the mechanisms that underlie the development of CKD after COVID-19. Health services research is also needed to understand and mitigate health disparities that are potentially worsened by COVID-19. Leveraging electronic health records of the State Medicaid databases that provide care for vulnerable patients in the USA may be helpful.
Some changes in health care due to COVID-19 are likely to persist even after the pandemic. For example, the move towards the use of telemedicine, especially in the post-discharge setting, will continue. As telemedicine is an important tool for preventive and population health, understanding barriers to its use in some patient groups, such as those with low socioeconomic status, will be important. Finally, intervention studies to prevent incident CKD and progression of kidney disease will be paramount in reducing long-term morbidity and mortality after COVID-19.
The pandemic has worsened disparities in health care, which may impact patients [with] CKD
In conclusion, the COVID-19 pandemic provides a unique opportunity to advance our understanding of how infection-associated AKI might worsen CKD and to develop novel therapies to delay progression of kidney disease. The pandemic has worsened disparities in health care, which may impact patients who are at-risk of or have CKD. Efforts to understand the effect of these disparities and identify steps to mitigate them should be an important focus of future research.
Silver, S. A. et al. The prevalence of acute kidney injury in patients hospitalized with COVID-19 infection: a systematic review and meta-analysis. Kidney Med. 3, 83–98 (2021).
Nadim, M. K. et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat. Rev. Nephrol. 16, 747–764 (2020).
Findling, M. G., Blendon, R. J. & Benson, J. M. Delayed care with harmful health consequences — reported experiences from national surveys during coronavirus disease 2019. JAMA Health Forum 1, e201463 (2020).
Prescott, H. C. et al. Understanding and enhancing sepsis survivorship. Priorities for research and practice. Am. J. Respir. Crit. Care Med. 200, 972–981 (2019).
Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259–264 (2021).
Huang, C. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 397, 220–232 (2021).
Puthumana, J. et al. Biomarkers of inflammation and repair in kidney disease progression. J. Clin. Invest. 131, e139927 (2021).
Haendel, M. A. et al. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J. Am. Med. Inform. Assoc. 28, 427–443 (2021).
National Institutes of Health. Research Opportunity Announcement OTA-21-015B. Post-acute sequelae of SARS-CoV-2 infection initiative: SARS-CoV-2 recovery cohort studies. NIH https://covid19.nih.gov/sites/default/files/2021-02/PASC-ROA-OTA-Recovery-Cohort-Studies.pdf (2021).
Yende, S., Iwashyna, T. J. & Angus, D. C. Interplay between sepsis and chronic health. Trends Mol. Med. 20, 234–238 (2014).
S.Y. has received funding from the Patient-centered Outcomes Research Institute (PCORI) and NIH. C.R.P. is supported by NIH grants, is a member of the advisory board of and owns equity in RenalytixAI, and serves as a consultant for Genfit and Novartis. The views expressed in this document do not represent the views of the Department of Veterans Affairs or funding agencies.
About this article
Cite this article
Yende, S., Parikh, C.R. Long COVID and kidney disease. Nat Rev Nephrol 17, 792–793 (2021). https://doi.org/10.1038/s41581-021-00487-3
This article is cited by
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2022)
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2022)
Cellular and Molecular Neurobiology (2022)
Nature Reviews Nephrology (2022)